- Home
- LNKB vs GALT Comparison
LNKB vs GALT Comparison
Compare LNKB & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | GALT |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.4M | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LNKB | GALT |
|---|---|---|
| Price | $8.45 | $6.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.00 | $6.00 |
| AVG Volume (30 Days) | 152.9K | ★ 465.8K |
| Earning Date | 01-26-2026 | 11-14-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 512.12 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $122,594,000.00 | N/A |
| Revenue This Year | $18.38 | N/A |
| Revenue Next Year | $0.35 | N/A |
| P/E Ratio | $8.03 | ★ N/A |
| Revenue Growth | ★ 42.32 | N/A |
| 52 Week Low | $6.09 | $0.73 |
| 52 Week High | $8.33 | $6.66 |
Technical Indicators
Market Signals| Indicator | LNKB | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 75.88 | 61.13 |
| Support Level | $7.59 | $5.10 |
| Resistance Level | $8.15 | $6.32 |
| Average True Range (ATR) | 0.25 | 0.56 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 89.58 | 88.92 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.